Abstract Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has well-described rapid antidepressant effects in clinical studies of individuals with treatment-resistant major depressive disorder (MDD). Preclinical studies investigating the effects of ketamine on brain-derived neurotrophic factor (BDNF) and on sleep slow wave activity (SWA) support its use as a prototype for investigating the neuroplastic mechanisms presumably involved in the mechanism of rapidly acting antidepressants. This review discusses human EEG slow wave sleep parameters and plasma BDNF as central and peripheral surrogate markers of plasticity, and their use in assessing ketamine's effects. Acutely, ketamine elevates BDNF levels, as well as early night SWA and highamplitude slow waves; each of these measures correlates with change in mood in depressed patients who respond to ketamine. The slow wave effects are limited to the first night postinfusion, suggesting that their increase is part of an early cascade of events triggering improved mood. Increased total sleep and decreased waking occur during the first and second night post infusion, suggesting that these measures are associated with the enduring treatment response observed with ketamine.
Introduction
Delayed onset of antidepressant action is a major limitation of existing antidepressant therapies. Several large effectiveness studies conducted in patients with major depressive disorder (MDD) indicate that less than 40 % of patients treated with standard antidepressants-either mono-or combined therapy-achieved remission within 10-14 weeks [1] [2] [3] , thus highlighting the need for novel treatment approaches. Novel treatment strategies as well as greater understanding of their molecular underpinnings might be identified by examining the molecular mechanisms that mediate the antidepressant effects of existing rapid-acting interventions such as sleep deprivation (SD), ketamine, scopolamine and electroconvulsive therapy (ECT) [4] [5] [6] [7] [8] .
Given that SD and ketamine enhance slow wave effects, an initial approach for uncovering the molecular underpinnings of these rapid antidepressant treatments might include examining the effects of ketamine and other rapidly acting drugs on electroencephalographic (EEG) sleep measures and brainderived neurotrophic factor (BDNF), which are central and peripheral putative surrogate biomarkers of synaptic plasticity. Key to the themes explored in this review, sleep interventions (e.g., SD) have been linked to synaptic plasticity, as suggested by increased sleep slow wave activity (SWA) and slow wave amplitude during recovery sleep. Further, both SD and ketamine increase the EEG SWA range (1-4 Hz) during non-REM (NREM) sleep and increase levels of BDNF [9] . Thus, these interventions may involve mechanisms key to understanding novel rapid antidepressant mechanisms.
Since the publication of the initial study identifying ketamine's rapid antidepressant effects [4] , numerous preclinical and clinical studies have examined its cellular and molecular effects as well as which clinical populations respond to ketamine, which drugs and doses are most effective, and what interventions might be used to delay relapse. Notably, clinical trials found that a single dose of sub-anesthetic ketamine induces a rapid (within 2 h) and sustained (1 to 2 weeks) antidepressant effect in patients with treatment-resistant MDD [10, 11] as well as bipolar depression [10, 12] . Additional glutamatergic plasticity-enhancing agents have been studied for the treatment of mood disorders, including subunit selective NMDA antagonists, glutamate release-reducing agents, and (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid) (AMPA) potentiators. Evidence suggests that all of these agents have potential as fast-acting antidepressants. Further, preclinical studies using different behavioral paradigms have similarly shown that the noncompetitive NMDA receptor antagonist ketamine has robust antidepressant properties [13, 14] . Combining these behavioral findings with those from cellular and molecular studies has significantly advanced our understanding of ketamine's antidepressant properties.
The purpose of this article is to briefly review the cellular and molecular mechanisms of ketamine's rapid antidepressant effects while highlighting the association between biomarkers of synaptic plasticity, sleep slow waves, and BDNF. The article will also discuss recent findings of current clinical investigations of ketamine's rapid antidepressant effects on BDNF and sleep slow waves in MDD and bipolar depression.
Ketamine: Cellular and Molecular Mechanisms
Ketamine exerts its initial rapid antidepressant properties via the NMDA receptor blockade and a prolonged change in glutamatergic signaling downstream of the NMDA blockade, ultimately resulting in increased synaptic strength and plasticity. Current research efforts have focused on uncovering the sequence of events that lead from blockade to rapid improvement in mood, cognition and behavior. Experiments investigating the role of glutamatergic transmission indicate that blockade of NMDA receptor-induced firing of gamma aminobutyric acid (GABA)ergic interneurons disinhibits glutamatergic pyramidal cells [15] , thus increasing glutamate release and activation of AMPA receptors, and culminating in an activity-dependent release of BDNF [13, 16••] . Ultimately changes in glutamatergic transmission activate the mammalian target of rapamycin (mTOR) signaling pathway and affect downstream structural changes in dendritic spines and local synaptic protein synthesis, including BDNF [17•] . BDNF secretion, activation of the tropomyosin-receptor-kinase B (TrkB) receptor, and downstream trafficking lead to further dendritic structural complexity, spine and BDNF synthesis, and synaptic plasticity. The functional effects of BDNF trafficking are compromised by polymorphisms such as BDNF Val66Met [18, 19] . Ultimately changes in critical local neuronal circuits converge via enhanced synaptic plasticity and neuronal synchronization, especially in areas involved in mood and behavior, to produce rapid antidepressant effects [11, 13] .
Notable in these observations is that manipulation of many steps in this signaling cascade either replicate or reverse the effects of ketamine in various rodent models of depression. For instance, the multi-day antidepressant effects of ketamine, as well as the synaptic spine production associated with its use, are blocked by rapamycin, which prevents activation of the mTOR pathway [13, 16••] . In addition, the effects of chronic unpredictable stress (decreased spine density, depressivelike behavior) are known to be reversed with ketamine [20] ; rapamycin similarly blocks ketamine's effects. An alternative interpretation is that the blockade of spontaneous (rather than evoked) glutamatergic activation of NMDA receptor blockade is critical to ketamine's mechanism of action [21••] , resulting in the inability to activate eukaryotic elongation factor 2 (eEF2) kinase, blunting of eFF2 phosphorylation, and BDNF derepression [22] . Further research is needed to discriminate between these mechanisms. Finally, inhibition of rapid (30 min) BDNF synthesis by anisomycin after ketamine treatment prevented the long-term behavioral effects of ketamine measured with the forced swim test [21••] .
Sleep and Plasticity
Demonstrating increased synaptic plasticity in humans following ketamine administration is a challenging undertaking, especially in a clinical population of patients with severe treatment-resistant depression. However, work from the Tononi laboratory at the University of Wisconsin suggests that some electrophysiological measures-such as sleep EEG and evoked potentials-are reliable indicators of increased synaptic plasticity in humans. In fact, high-density EEG studies have shown that manipulations leading to synaptic potentiation in local cortical circuits [rotation learning, high-frequency transcranial magnetic stimulation (TMS)] lead to a local increases in SWA during subsequent sleep [23] ; in contrast, manipulations leading to synaptic depression (arm immobilization) lead to a local reduction in SWA [24] . Largescale computer simulations, validated by experimental studies in both rats and animals, have demonstrated that sleep SWA directly reflects synaptic strength due to changes in neural synchronization and recruitment [25, 26] . Moreover, these studies have shown that the slopes of sleep slow waves represent a highly sensitive marker of synaptic strength in underlying circuits [27] .
Several studies that directly examined the effect of BDNF on EEG sleep slow waves have also noted a close relationship between SWA and BDNF [9, 28] . Interestingly, these studies found that SWA is increased by intrahemispheric infusion of BDNF, diminished by BDNF antagonism [9] , and increased by behavioral interventions that increase central levels of BDNF [28] as well as the plasticity-related genes Arc, Homer, and NGFI-A [28] . Acoustic suppression of SWA activity and its capacity to diminish perceptual learning [29] further supports the possibility that decreased levels of slow wave sleep per se may contribute to cognitive and memory deficits in some depressed patients. Recent clinical studies have established another link between BDNF, sleep slow wave activity, and mood by showing that human carriers of the BDNF Met allele of the Val66Met polymorphism have reduced production of sleep slow waves [30] . Another study found that individuals with this polymorphism were less likely to respond to ketamine than the Val/Val allele [31] .
Sleep Deprivation (And Other Sleep Interventions) as Rapidly Acting Interventions and Extenders of Remission
The robust and rapid antidepressant efficacy of SD therapy underlies its continued clinical and research use for over 5 decades [32, 33] . SD leads to increased slow wave sleep during recovery sleep, suggesting that the deficient production of sleep slow waves in many patients with depression may be part of a pathology that can be briefly reversed by the homeostatic processes activated by SD [34] . More recently, the synaptic homeostasis hypothesis [35] , which extends the two-process model of sleep regulation described above [36] , has provided a conceptual and cellular framework to understand the possible molecular underpinnings of SD therapy. Specifically, SD is associated with increased neurotrophic factors such as BDNF and VEGF [37, 38] as well as with synaptic plasticity and rapid remission of depression; notably, many of the same effects are observed with ketamine treatment. However, it is currently not known whether response to SD therapy predicts response to ketamine, which would provide support for a common mechanism underlying rapid antidepressant effects.
Interestingly, while SD therapy and ketamine treatment both exert rapid antidepressant effects, these interventions differ with regard to course of remission and relapse. One distinction concerns the depressogenic role of sleep in relapse, a core problem with SD therapy. After the rapid response to SD therapy, sleep per se contributes to relapse, an effect often seen following the first night of recovery sleep, or possibly sooner following a daytime nap. In contrast, the rapid antidepressant effects of ketamine are not rapidly or robustly reversed by sleep. However, careful evaluation of this point is needed since a differential response to recovery sleep would suggest that SD and ketamine differ with respect to synaptic downscaling, the process associated with restorative function of sleep, sleep homeostasis [35] , and the course of remission.
Relatedly, time to relapse can be rapid (<1 day) after SD therapy, but often extends past 4 to 7 days in those patients who respond to a single infusion of ketamine. Several adjunct interventions [lithium, selective serotonin reuptake inhibitors (SSRIs), phototherapy, chronotherapy] have been shown to prolong response to SD therapy [39] [40] [41] . While repeated ketamine infusions extend the antidepressant response [42] [43] [44] , concurrent treatment with riluzole, a presynaptic inhibitor of glutamate release and enhancer of AMPA trafficking and glial glutamate reuptake, does not alter the course of remission [45, 46] . Another study noted that treatment with the mood stabilizers lithium or valproate did not alter the relapse rate in individuals with bipolar depression treated with ketamine [10] , but it remains unknown whether they may extend the interval to relapse.
The contribution of sleep in affecting the response to ketamine has not been directly evaluated. Microsleep episodes [47] as well as nighttime sleep restriction [48] have been shown to blunt and extend response to SD therapy [47] respectively, but similar research with ketamine has not been conducted. Taken together with the fact that altered glutamate transmission contributes to the rapid antidepressant mechanism of both SD therapy [40, 49, 50] 
Effects of Ketamine on Sleep and Slow Waves in Treatment-Resistant MDD
Earlier studies indicated that the NMDA antagonists ketamine [51] and MK-801 [52] increased SWA. Given the rapid antidepressant effects associated with SD, as well as its ability to increase neurotrophins and SWA, we hypothesized that similar changes might also be associated with rapid mood change after ketamine infusion. To test the hypothesis that ketamine increased synaptic strength in conjunction with its rapid effects on mood, sleep slow waves (a putative central marker of plasticity) and BDNF (a peripheral marker of plasticity) were measured [53•] . Montgomery-Åsberg Depression Rating Scale (MADRS) scores rapidly decrease and remain low for several days following ketamine treatment in patients with treatment-resistant MDD. In our recent clinical investigation of ketamine and sleep, plasma BDNF levels, SWA, and high amplitude waves increased after ketamine [53•] . SWA and amplitude effects were increased during early sleep (first nREM period). These slow wave effects were limited to the first night after ketamine infusion. Importantly, the first-night EEG slow wave changes were accompanied by an increase in slow wave slope, consistent with increased synaptic strength [27] . Further, in those patients who responded to ketamine (defined as a greater than 50 % reduction in MADRS score 230 min after infusion), changes in BDNF levels were proportional to changes in EEG slow wave parameters, suggesting that enhanced synaptic plasticity is part of the physiological mechanism underlying the rapid antidepressant effects of NMDA antagonists.
Ketamine's effects on sleep EEG were specific to low frequencies corresponding to the SWA range. Further, ketamine did not increase SWA in waking epochs prior to sleep onset, indicating that the change was sleep-specific. Negligible effects of the ketamine infusion on sleep EEG were measured in bands corresponding to sleep spindles, and alpha or theta frequencies [53•] .
In addition to significant ketamine-induced increases in levels of BDNF, SWA, high amplitude waves, and slope, the observed correlations between BDNF levels and slow wave parameters indicate a strong relationship between these measures. Specifically, the positive correlations between changes in logBDNF and changes in relative SWA, as well as between changes in logBDNF and the incidence of high amplitude sleep slow waves, are consistent with the association between these markers of synaptic plasticity [9, 28] . Interestingly, most patients classified as ketamine responders had low levels of SWA and BDNF at baseline, followed by large increases in both of these measures after ketamine infusion [53•] . Indeed, the low baseline production of SWA during the first nREM period predicted later response to ketamine in responders [54] , suggesting that lower brain plasticity is a marker of ketamine response, which is reversed by ketamine in responders [53•, 55] .
Significant day-to-day changes in sleep variables appear to provide markers of an underlying sequence of signaling cascades associated with immediate (day one) and continued (day 2) mood response [53•] involving synaptic plasticity and BDNF. Of special interest is the observation that ketamineinduced increases in sleep slow waves were confined to the first night after treatment but were then decreased toward baseline levels on night two (Fig. 1) . The timing of a day 1 increase in slow waves, followed by a decline toward baseline levels on day 2, is consistent with preclinical findings of Autry et al. [21••] of an acute day 1 (30 min) increase in BDNF levels, followed by a day 2 decrease, and may be particularly important given the previously described association between BDNF and slow wave production [9, 28] . Thus, the decline of sleep slow waves on day 2 would be consistent with a decline in BDNF levels. However, because BDNF was not measured in the clinical study, this point requires further investigation.
It is also important to note that there was an increase in total sleep and a decrease in waking during both the first and second nights following ketamine infusion, indicating that persisting changes related to sleep consolidation may contribute to continued antidepressant mood effects. Overall, the increase in sleep slow waves appears to be a marker of the acute increase in BDNF and rapid antidepressant effects, whereas improved sleep quality is associated with extended mood response. Studies are ongoing to identify additional mediators of the extended mood response.
Effect of Ketamine on Sleep and Slow Waves in Patients with Bipolar Disorder Treated with Mood Stabilizers
Sleep slow waves were examined in a group of patients with bipolar depression (n=15, mean baseline MADRS=34.5) during a baseline night and on the first night after ketamine infusion; these patients were also receiving maintenance doses of the mood stabilizers lithium (n=11) or valproate (n=4). Importantly, ketamine effects on slow wave activity differed from patients with MDD. In contrast to the ketamineinduced increases in sleep slow waves described above in individuals with MDD, ketamine did not increase EEG sleep slow waves relative to baseline in individuals with bipolar depression [56] . Spectral and slow wave analysis showed that ketamine had no effect on slow wave power or the amplitude distribution of slow waves, and no correlation was observed between high (>80 μV) amplitude wave count and MADRS score. Interestingly in BP, ketamine decreased early (nREM1) relative SWA (BL nR1=1.15±0.1; Day1 nR1=0.98±0.1; BL nR2=1.14±0.08; Day 1=1.21±0.09; BL nR3=0.9±0.07; Day 1=0.8±0.07; mean±SEM). Several factors might contribute to this discrepancy between BP and MDD. First, individuals with bipolar depression and MDD may differ in sleep slow wave responses to ketamine because of biological differences in neuroplastic and sleep homeostatic mechanisms (i.e., our BP patients tended to have greater SWS than the MDD). Secondly, suppression of SWA is also associated with an antidepressant response [57] . Thus, in BP, the ketamineinduced decrease in early SWA may be related to antidepressant effects in BP, but further research is required to evaluate this possibility, as well as the association among BDNF, SWA, and mood. Alternatively, maintenance doses of lithium or valproate may have altered the response to ketamine. Both lithium and valproate are known to increase slow wave sleep and enhance plasticity [58] [59] [60] [61] [62] [63] , as well as inhibit glycogen synthase kinase-3 (GSK3) [64] , which is necessary for ketamine's antidepressant effects [65] . Their effects on second messenger systems and associated synaptic strength during maintenance therapy are also likely to increase baseline levels of SWA, thus creating a ceiling effect, so that ketamine-induced slow wave increases could not occur. A critical finding here is that ketamine's ability to enhance sleep slow waves is not necessary for mood response (e.g., blocking production has no effect on mood). Rather, the enhanced production of slow waves present in MDD is a marker of plasticity and increased BDNF, but might be masked by drug effects. Alternately, the marker may vary across different patient groups. This study highlights the need for further studies to confirm the link between mood and central (sleep slow waves) or peripheral (BDNF) markers of synaptic plasticity. Critical to these studies is the need to examine ketamine challenges in both drug-free depressed and healthy populations. It is important to note that while biomarkers such as sleep slow waves are promising tools while developing novel drugs and identifying target populations, ongoing drug use might compromise their utility.
Conclusion
Remarkable progress has been made in the last 5 years to identify molecular and cellular mechanisms critical to ketamine's rapid antidepressant effects. In particular, combining two markers of synaptic plasticity, BDNF levels and EEG sleep slow waves, has proven to be an effective approach for identifying ketamine's capacity to increase synaptic strength. Nevertheless, numerous fundamental questions remain to be answered regarding the association between sleep, slow waves, and the time course of mood response to ketamine because these measures appear to have different response times. Identifying markers of ketamine's prolonged mood effects as well as the utility of baseline slow wave sleep-a possible marker of brain plasticity-to predict mood response to ketamine will be important for optimizing treatment outcome. It should also be noted that, despite the promising nature of the research investigating ketamine's effects on sleep slow waves, the subject groups have largely comprised individuals with treatment-resistant depression; thus, replication of these findings is critical. Future studies will need to address the effects of ketamine on sleep in other drug-free patient and healthy control populations.
As noted above, sleep slow wave measures (SWA, amplitude, and slope) appear to be related to an acute day one rise in BDNF levels as well as rapid antidepressant response; these measures (and preclinical BDNF levels) decline on day 2 during remission. In contrast, increased total sleep and improved sleep continuity on day 2 are associated with the extended remission. Further studies are needed to identify additional markers of plasticity and extended mood response. Finally, if interventions that produce rapid antidepressant effects share a common mechanism that increase synaptic strength, one might anticipate that such treatments also have similar effects on EEG sleep slow waves measures. Such studies are essential to uncovering key components of the rapid antidepressant response mechanism as well as to identifying additional novel treatment interventions.
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